Skip to main content
SpringerLink
Log in

Pancreatic Cancer

  • Chapter
Tropical Hemato-Oncology

  • 728 Accesses

Abstract

Pancreatic adenocarcinoma is the fourth most frequent cause of tumor-related death in the Western world. Its prognosis is poor with a median survival between 5 and 8 months and a median 5-year survival less than 5 %. Few patients present with a resectable tumor and even with a curative surgery, 70–80 % of them recur. A great majority of them present at an advanced stage, either with metastatic or locally advanced disease. The standard treatment of metastatic and locally advanced pancreatic cancer patients is based on chemotherapy. Recent progress has been made in metastatic setting, especially with chemotherapy regimens such as FOLFIRINOX and new agents such as nab-paclitaxel. Unlike other cancers, no benefit has, until now, been translated into the clinics by the progress of molecular biology and targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ajao OG, Abioye AA (1980) Pancreatic carcinoma. J Natl Med Assoc 72(6):589–590

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, Macari M, Megibow AJ, Miller FH, Mortele KJ, Merchant NB, Minter RM, Tamm EP, Sahani DV, Simeone DM (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 146(1):291–304

    Google Scholar 

  3. Attard CL, Brown S, Alloul K, Moore MJ (2014) Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Curr Oncol 21(1):e41–e51

    Google Scholar 

  4. Balachandran A, Bhosale PR, Charnsangavej C, Tamm EP (2014) Imaging of pancreatic neoplasms. Surg Oncol Clin N Am 23(4):751–788

    Google Scholar 

  5. Balakrishnan V, Unnikrishnan AG, Thomas V, Choudhuri G, Veeraraju P, Singh SP, Garg P, Pai CG, Devi RN, Bhasin D, Jayanthi V, Premalatha N, Chacko A, Kar P, Rai RR, Rajan R, Subhalal N, Mehta R, Mishra SP, Dwivedi M, Vinayakumar KR, Jain AK, Biswas K, Mathai S, Varghese J, Ramesh H, Alexander T, Philip J, Raj VV, Vinodkumar A, Mukevar S, Sawant P, Nair P, Kumar H, Sudhindran S, Dhar P, Sudheer OV, Sundaram KR, Tantri BV, Singh D, Nath TR (2008) Chronic pancreatitis. A prospective nationwide study of 1,086 subjects from India. JOP 9(5):593–600. doi:v09i05a02 [pii]

    Google Scholar 

  6. Bornman PC, Beckingham IJ (2001) ABC of diseases of liver, pancreas, and biliary system. Pancreatic tumours. BMJ 322(7288):721–723

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ (1998) Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 42(1):92–96

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413

    CAS  PubMed  Google Scholar 

  9. Edge SB, Byrd DR, Compton C C (2010) AJCC cancer staging manual. United States and Canadian Academy of Pathology, Inc.

    Google Scholar 

  10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386

    Google Scholar 

  11. Gonzalo-Marin J, Vila JJ, Perez-Miranda M (2014) Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol 6(9):360–368

    Google Scholar 

  12. Hollmann S, Alloul K, Attard C, Kavan P (2014) PD-0018AN Indirect treatment comparison and cost-effectiveness analysis comparing Folfirinox with nab-paclitaxel plus gemcitabine for first-line treatment for patients with metastatic pancreatic cancer. Ann Oncol 25(suppl 2):ii11–ii12

    Google Scholar 

  13. Huxley R, Ansary-Moghaddam A, Berrington de GA, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11):2076–2083

    Google Scholar 

  14. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836–847

    Google Scholar 

  15. Kendig CE, Samuel JC, Tyson AF, Khoury AL, Boschini LP, Mabedi C, Cairns BA, Varela C, Shores CG, Charles AG (2013) Cancer treatment in Malawi: a disease of palliation. World J Oncol 4(3):142–146

    PubMed Central  PubMed  Google Scholar 

  16. Ma J, Siegel R, Jemal A (2013) Pancreatic cancer death rates by race among US men and women, 1970–2009. J Natl Cancer Inst 105(22):1694–1700

    Google Scholar 

  17. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081

    Google Scholar 

  18. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310(14):1473–1481

    Google Scholar 

  19. Paliwal S, Bhaskar S, Chandak GR (2014) Genetic and phenotypic heterogeneity in tropical calcific pancreatitis. World J Gastroenterol 20(46):17314–17323

    Google Scholar 

  20. Permuth-Wey J, Egan KM (2009) Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 8(2):109–117

    Google Scholar 

  21. Putzer D, Jaschke W (2015) Radiological evaluation of focal pancreatic lesions. Dig Dis 33(1):91–98

    Google Scholar 

  22. Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CHJ (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40(7):794–804

    Article  CAS  PubMed  Google Scholar 

  23. Saif MW (2011) Pancreatic neoplasm in 2011: an update. JOP 12(4):316–321. doi:v12i04a01 [pii]

    Google Scholar 

  24. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241

    Google Scholar 

  25. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29

    Google Scholar 

  26. Singhal MK, Kapoor A, Bagri PK, Narayan S, Singh D, Nirban RK, Singh G, Maharia S, Kumari P, Jakhar SL, Beniwal S, Sharma N, Harsh K, Kumar HS, Sharma A, Bardia M (2014) 617PDA Phase III trial comparing Folfirinox versus gemcitabine for metastatic pancreatic cancer. Ann Oncol 25(suppl 4):iv210–iv211

    Google Scholar 

  27. Taylor MC, McLeod RS, Langer B (2000) Biliary stenting versus bypass surgery for the palliation of malignant distal bile duct obstruction: a meta-analysis. Liver Transpl 6(3):302–308

    Google Scholar 

  28. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van CE, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Google Scholar 

  29. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, Hruban RH, Cote ML, McWilliams RR, Roberts NJ, Cannon-Albright LA, Li D, Moyes K, Wenstrup RJ, Hartman AR, Seminara D, Klein AP, Petersen GM (2014) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med

    Google Scholar 

  30. Zovak M, Muzina MD, Glavcic G (2014) Pancreatic surgery: evolution and current tailored approach. Hepatobiliary Surg Nutr 3(5):247–258

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Centre Léon-Bérard, University of Lyon, 28 rue Laënnec, 69008, Lyon, France

    Christelle de la Fouchardière

  2. Medical Oncology Outpatients Clinic, Centre Hospitalier de Cayenne, Cayenne, Guyane Française

    Béatrice Cenciu

Authors
  1. Christelle de la Fouchardière
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Béatrice Cenciu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christelle de la Fouchardière .

Editor information

Editors and Affiliations

  1. Medical Oncology, Claude-Bernard-Lyon1 University, Lyon, France

    Jean-Pierre Droz

  2. Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Bernard Carme

  3. Service de dermatologie, Centre hospitalier de Cayenne, Cayenne, French Guiana

    Pierre Couppié

  4. Guyane, INSERM CIC 1424, Centre d'Investigation Clinique Antilles, Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Mathieu Nacher

  5. Service d’hémato-oncologie, Hôpital Saint-Louis, Paris, France

    Catherine Thiéblemont

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

de la Fouchardière, C., Cenciu, B. (2015). Pancreatic Cancer. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_36

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18257-5_36

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18256-8

  • Online ISBN: 978-3-319-18257-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation